Clinical Trial

Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of the study is to evaluate the efficacy and safety of the combination of niraparib and dostarlimab in patients participants with advanced relapsed/refractory penile cancer.
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2022-08-31; most recent amendment 2025-12-03.
Status change: Not Yet Recruiting → Recruiting 2022-11-23
Trial Details
NCT Number NCT05526989
Lead Sponsor H. Lee Moffitt Cancer Center and Research Institute
Collaborators: GlaxoSmithKline
Conditions Penile Carcinoma
Enrollment 25 participants
Start Date 2022-12-28
Primary Completion 2026-11 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2025-12-04